by taramac | Jan 19, 2021 | Uncategorized
TALLC issues new Corporate Presentation January 19, 2021 View the...
by taramac | Dec 4, 2020 | Uncategorized
Dr. Damon Smith at Biotech Show Case Hear Dr. Damon Smith CEO of TALLC present new data on TA-A001 for ocular inflammation at Biotech Show Case January 11-15...
by taramac | Nov 17, 2020 | Uncategorized
TALLC at the Ophthalmology Innovation Summit TALLC to introduce TA-A001, our proprietary CB2R agonist, and the enabling effects of SmartCelle ocular delivery technology at the Ophthalmology Innovation Summit: Drug Delivery Showcase. OIS Drug Delivery Innovation...
by taramac | Jul 7, 2020 | Uncategorized
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001 July 7, 2020 Montreal, Quebec Life Science Newswire – TALLC Corporation Inc. (TALLC) a pioneering pharmaceutical company using proprietary new molecular entities to...
by taramac | May 30, 2020 | Uncategorized
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001 June 3rd, 2020 Laval Quebec (GLOBE NEWSIRE) – Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the...
